Skip to main content

September 2025

Crack GPAT — Prepare for GPAT Online 

Interview for Ph.D, M.Pharm, MSc in ADL, R&D Synthesis at AMI Lifesciences

Develop cost-effective, high-quality, and eco-friendly processes as per ICH guidelines. Optimize lab processes, validate products, and transfer technology to pilot plant.
Require Quality Management System Executive at Panacea Biotec
Handling of Quality Management System activities i.e. Change Control, Deviation, Market Complaints, CAPA, Investigation.
Zydus's Saroglitazar shows positive results in Patients with Primary Biliary Cholangitis
Zydus Therapeutics, a wholly owned subsidiary of Zydus Lifesciences Ltd., a global innovation led healthcare company, announced positive topline results from the pivotal EPICS-III Phase 2(b)/3 clinical trial.
Government boosts rabies control through vaccines, training, and model anti-rabies clinics
The Ministry of Health & Family Welfare through National Rabies Control Program (NRCP) is undertaking strengthening of surveillance of all animal bites in all States/UTs. Data on dog and other animal bite cases and related deaths are reported by all States/UTs, through Integrated Health Information Platform
India making major strides towards self-reliance in high end medical devices
Shri Amit Agrawal, Secretary, Department of Pharmaceuticals, highlighted Indias transformation into an emerging hub for medical technology at the 17th CII Global MedTech Summit, themed Innovating for a Healthier Future – Advancing MedTech for Global Impact: Make in India, Make for the World, in New Delhi.
SEC recommends approval for Bayer’s Darolutamide tablets for Prostate Cancer treatment in India
The Subject Expert Committee Oncology, in its 25th meeting held at CDSCO headquarters, has recommended granting permission to Bayer Pharmaceuticals Pvt. Ltd. for the manufacture and marketing of Darolutamide Film-Coated Tablets 300 mg in India.
Astrazeneca's Baxdrostat reduces BP in patients with uncontrolled hypertension in clinical trials
Positive full results from the ​BaxHTN Phase III trial showed AstraZeneca ​baxdrostat, demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure (SBP) at two doses 2mg and 1mg compared with placebo at 12 weeks. Results were seen in patients with hard-to-control uncontrolled and resistant hypertension who received baxdrostat or placebo on top of standard of care.